Evolus (NASDAQ:EOLS) Announces Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Evolus (NASDAQ:EOLS) posted its earnings results on Wednesday. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.13), FiscalAI reports. The business had revenue of $77.95 million during the quarter, compared to the consensus estimate of $77.58 million.

Here are the key takeaways from Evolus’ conference call:

• Third-quarter revenue rose 13% to $78 million, including $70.1 million in toxin revenue and $7.9 million in HA revenue. Adjusted EBITDA was positive for the fourth consecutive quarter at $1.2 million; year-to-date adjusted EBITDA improved to $6.4 million from a loss of $16.5 million a year earlier.
• Evolus reaffirmed full-year revenue guidance of $330 million–$337 million and adjusted gross margin guidance of 67%–67.5%, while lowering its non-GAAP operating expense outlook to $210 million–$213 million. It also maintained its low- to mid-single-digit adjusted EBITDA margin outlook for 2026 and 2028 targets of $450 million–$500 million in revenue and 13%–15% adjusted EBITDA margins.
• Commercial traction broadened: the company added more than 500 purchasing accounts, bringing its cumulative customer base above 19,000, while more than 4,500 customers have purchased Evolysse. Evolus Rewards membership increased 23% year over year to more than 1.6 million, and the company said about 70% of existing patients return for repeat treatment.
• The company expects FDA approval of Evolysse Sculpt in the fourth quarter of 2026 and anticipates submitting the Lips PMA before year-end, with a launch expected in early 2028. Profhilo is a longer-term U.S. opportunity with approval anticipated around 2030; the hair-growth asset remains an early-stage option subject to human data.
• The FDA issued an untitled letter concerning a single Jeuveau social-media post. Management said the post was removed, the concern would be addressed, and the letter would not affect Jeuveau promotion or the business.

Evolus Stock Performance

EOLS stock traded up $0.10 during trading on Wednesday, hitting $7.47. The stock had a trading volume of 830,278 shares, compared to its average volume of 698,632. The company’s 50 day moving average price is $7.89 and its two-hundred day moving average price is $6.29. Evolus has a 1-year low of $3.86 and a 1-year high of $9.31. The stock has a market cap of $493.39 million, a price-to-earnings ratio of -14.37 and a beta of 1.38.

Wall Street Analyst Weigh In

EOLS has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evolus in a research note on Friday, September 11th. HC Wainwright reissued a “buy” rating and issued a $13.00 price objective on shares of Evolus in a research note on Tuesday, August 25th. Finally, Wall Street Zen upgraded shares of Evolus from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $14.50.

Insider Transactions at Evolus

In other Evolus news, insider David Moatazedi sold 105,108 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $9.04, for a total transaction of $950,176.32. Following the sale, the insider directly owned 499,592 shares of the company’s stock, valued at $4,516,311.68. This trade represents a 17.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 5.00% of the company’s stock.

About Evolus

Evolus, Inc is a commercial-stage medical aesthetics company focused on developing and marketing products for physicians and other licensed aesthetic providers. The company’s business is centered on minimally invasive treatments intended to address facial lines, wrinkles and other visible signs of aging.

Evolus’ primary product is Jeuveau (prabotulinumtoxinA-xvfs), an injectable botulinum toxin approved by the U.S. Food and Drug Administration for the temporary improvement of moderate to severe glabellar lines, commonly known as “frown lines,” in adults.